CD274 and neoplasm: We found that in contrast to <1% PD-L1 expression in patients with weak cytotoxicity (RES23), patients with strong (RES38) and moderate (RES19) cytotoxicities showed 1–49% PD-L1 expression on tumor cells (Table 1, Supplementary Fig. S11).